BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Clinical Outcome
11 results:

  • 1. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
    Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
    Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Loss of tumour-specific atm protein expression is an independent prognostic factor in early resected NSCLC.
    Petersen LF; Klimowicz AC; Otsuka S; Elegbede AA; Petrillo SK; Williamson T; Williamson CT; Konno M; Lees-Miller SP; Hao D; Morris D; Magliocco AM; Bebb DG
    Oncotarget; 2017 Jun; 8(24):38326-38336. PubMed ID: 28418844
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
    Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis.
    Xuan ZX; Zhang S; Yuan SJ; Wang W; Yu J
    World J Surg Oncol; 2016 Sep; 14(1):237. PubMed ID: 27589869
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. atm protein is deficient in over 40% of lung adenocarcinomas.
    Villaruz LC; Jones H; Dacic S; Abberbock S; Kurland BF; Stabile LP; Siegfried JM; Conrads TP; Smith NR; O'Connor MJ; Pierce AJ; Bakkenist CJ
    Oncotarget; 2016 Sep; 7(36):57714-57725. PubMed ID: 27259260
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
    Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
    J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic role of hypoxic inducible factor expression in non-small cell lung cancer: a meta-analysis.
    Li C; Lu HJ; Na FF; Deng L; Xue JX; Wang JW; Wang YQ; Li QL; Lu Y
    Asian Pac J Cancer Prev; 2013; 14(6):3607-12. PubMed ID: 23886153
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Different impact of IL10 haplotype on prognosis in lung squamous cell carcinoma and adenocarcinoma.
    Wang YC; Sung WW; Wang L; Cheng YW; Chen CY; Wu TC; Shieh SH; Lee H
    Anticancer Res; 2013 Jun; 33(6):2729-35. PubMed ID: 23749933
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.
    Dong J; Hu Z; Shu Y; Pan S; Chen W; Wang Y; Hu L; Jiang Y; Dai J; Ma H; Jin G; Shen H
    Mol Carcinog; 2012 Jul; 51(7):546-52. PubMed ID: 21739480
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
    Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.